Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3926-7267
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.85 billion
Profitability
Miscellaneous
Employees51,792
OptionableOptionable
Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions
What is Teva Pharmaceutical Industries' stock symbol?
Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."
How were Teva Pharmaceutical Industries' earnings last quarter?
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) posted its earnings results on Wednesday, February, 13th. The company reported $0.53 earnings per share for the quarter, hitting the consensus estimate of $0.53. The firm earned $4.56 billion during the quarter, compared to the consensus estimate of $4.52 billion. Teva Pharmaceutical Industries had a negative net margin of 11.40% and a positive return on equity of 18.57%. The company's revenue was down 15.5% on a year-over-year basis. During the same quarter last year, the company earned $0.93 earnings per share. View Teva Pharmaceutical Industries' Earnings History.
When is Teva Pharmaceutical Industries' next earnings date?
What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?
Teva Pharmaceutical Industries updated its FY19 earnings guidance on Wednesday, February, 13th. The company provided earnings per share (EPS) guidance of $2.20-2.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.82. The company issued revenue guidance of $17.0-17.4 billion, compared to the consensus revenue estimate of $17.99 billion.Teva Pharmaceutical Industries also updated its FY 2019 guidance to $2.20-2.50 EPS.
What price target have analysts set for TEVA?
20 Wall Street analysts have issued 12 month price objectives for Teva Pharmaceutical Industries' shares. Their forecasts range from $12.00 to $30.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $22.80 in the next year. This suggests a possible upside of 26.5% from the stock's current price. View Analyst Price Targets for Teva Pharmaceutical Industries.
What is the consensus analysts' recommendation for Teva Pharmaceutical Industries?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 1 sell rating, 12 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.
What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?
Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
- 1. According to Zacks Investment Research, "Teva is facing significant challenges in the form of accelerated generic competition for its blockbuster product Copaxone, new competition for other branded products, pricing erosion in the U.S. generics business and a massive debt load. Teva has a new organizational structure in place, is closing plants, cutting down its generics portfolio, divesting non-core assets, eliminating low-value R&D projects, and is reducing global workforce to revive growth. Though Teva is progressing well on these re-structuring activities and its financial position seems more stable than before, we believe the company has a long way to go before it gains stability and resumption of organic growth seems unlikely until 2020. Teva’s shares have underperformed the generic industry in the past six months. Estimates have remained stable ahead of Q4 earnings release. Teva has a positive record of earnings surprises. " (1/21/2019)
- 2. Maxim Group analysts commented, "Teva reported 3Q18 with revenues of $4.53B vs. $4.55B consensus and beat on the bottom line with non-GAAP EPS of $0.68 vs. $0.55. The beat was driven by positive impacts from the ongoing restructuring strategy with a spend base reduction of $2B YTD compared to 2017 (excluding FX) and on track to reach $3B by YE19." (11/1/2018)
- 3. Cantor Fitzgerald analysts commented, "We rate TEVA 12-month price target of $25. We like Teva’s stock and believe that there is a lot of value to be unlocked, but that it will take time for new leadership to return the business to growth. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (9/27/2018)
- 4. Mizuho analysts commented, "We lowered 2018 estimates due to weaker but note that stronger Copaxone and EpiPen could make up the difference. We reiterate our Buy rating and $28 PT, but have become more cautious on a timely migraine approval on Sept 16. We see shares as undervalued even if approval is delayed." (8/24/2018)
Has Teva Pharmaceutical Industries been receiving favorable news coverage?
News headlines about TEVA stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Are investors shorting Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries saw a decrease in short interest in January. As of January 31st, there was short interest totalling 24,516,652 shares, a decrease of 34.6% from the January 15th total of 37,492,387 shares. Based on an average trading volume of 6,994,019 shares, the short-interest ratio is presently 3.5 days. Approximately 2.3% of the company's stock are sold short. View Teva Pharmaceutical Industries' Current Options Chain.
Who are some of Teva Pharmaceutical Industries' key competitors?
Some companies that are related to Teva Pharmaceutical Industries include Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Allergan (AGN), Regeneron Pharmaceuticals (REGN), Zoetis (ZTS), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL) and Ono Pharmaceutical (OPHLF).
Who are Teva Pharmaceutical Industries' key executives?
Teva Pharmaceutical Industries' management team includes the folowing people:
- Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
- Mr. Michael McClellan, Exec. VP & CFO (Age 48)
- Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
- Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
- Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)
Who are Teva Pharmaceutical Industries' major shareholders?
Teva Pharmaceutical Industries' stock is owned by many different of institutional and retail investors. Top institutional investors include Brahman Capital Corp. (1.20%), Polaris Capital Management LLC (1.02%), Northern Trust Corp (0.66%), Harel Insurance Investments & Financial Services Ltd. (0.56%), Clal Insurance Enterprises Holdings Ltd (0.37%) and Menora Mivtachim Holdings LTD. (0.36%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.
Which major investors are selling Teva Pharmaceutical Industries stock?
TEVA stock was sold by a variety of institutional investors in the last quarter, including Eaton Vance Management, Acadian Asset Management LLC, Thornburg Investment Management Inc., Dimensional Fund Advisors LP, Mckinley Capital Management LLC Delaware, Millennium Management LLC, Commerzbank Aktiengesellschaft FI and Bank of Montreal Can. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
Which major investors are buying Teva Pharmaceutical Industries stock?
TEVA stock was acquired by a variety of institutional investors in the last quarter, including Brahman Capital Corp., Menora Mivtachim Holdings LTD., Harel Insurance Investments & Financial Services Ltd., Clal Insurance Enterprises Holdings Ltd, Principal Financial Group Inc., Noked Capital LTD, Los Angeles Capital Management & Equity Research Inc. and Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
How do I buy shares of Teva Pharmaceutical Industries?
Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teva Pharmaceutical Industries' stock price today?
One share of TEVA stock can currently be purchased for approximately $18.02.
How big of a company is Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries has a market capitalization of $18.32 billion and generates $18.85 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or $2.80 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.
What is Teva Pharmaceutical Industries' official website?
How can I contact Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]
MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
